1
|
Ge X, Meng W, Wang W, Ma H, Zhao S, Cui K. Causes of death in primary plasma cell leukemia differ from multiple myeloma: A STROBE-compliant descriptive study based on SEER database. Medicine (Baltimore) 2022; 101:e29578. [PMID: 35866755 PMCID: PMC9302293 DOI: 10.1097/md.0000000000029578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
The primary plasma cell leukemia (pPCL) is a rare but aggressive variant of multiple myeloma (MM). Few studies have focused on the differences in the causes of death between pPCL and MM. This study aimed to compare and evaluate the causes of death of patients with pPCL and MM. The data were collected from the Surveillance Epidemiology, and End Results (SEER) database. The demographic characteristics, survival, and causes of death in pPCL and MM patients were evaluated and compared. The competing risk regression model was performed to predict the cause of death. Between 1975 and 2009, the overall mortality rate was 96.13% and 88.71% for pPCL and MM, and the median survival was 9 and 26 months, respectively. In pPCL, leukemia caused 45.05% of the deaths, followed by myeloma (38.83%). In MM, myeloma was the leading cause of death, accounting for 74.89% of the deaths. Older age at diagnosis was a risk factor for dying of leukemia in pPCL patients (HR = 1.49, 95% CI: 1.16-1.91), while older age at death was associated with reduced risk (HR = 0.67, 95% CI: 0.52-0.86). Although the survival of pPCL patients increased with time periods of diagnosis since 1975 to 2009, the risk of dying of leukemia increased with the periods. For MM, most of the demographic characteristics were found to have independently predicting influence on the cause of death. Patients with pPCL and MM had distinct causes of death. Leukemia was the leading and the most serious cause of death in pPCL patients. The demographic factors could not predict the causes of death in pPCL. More large-scale and multi-center studies are needed to evaluate the effect of novel agents in pPCL patients, especially for patients who have progressed to leukemia.
Collapse
Affiliation(s)
- Xiaoyan Ge
- Department of Health Statistics, School of Public Health, Jinzhou Medical University, Jinzhou, Liaoning Province, P.R. China
| | - Weihan Meng
- Department of Health Statistics, School of Public Health, Jinzhou Medical University, Jinzhou, Liaoning Province, P.R. China
| | - Wenbo Wang
- Department of Health Statistics, School of Public Health, Jinzhou Medical University, Jinzhou, Liaoning Province, P.R. China
| | - Honglin Ma
- Department of Health Statistics, School of Public Health, Jinzhou Medical University, Jinzhou, Liaoning Province, P.R. China
| | - Siqi Zhao
- Department of Health Statistics, School of Public Health, Jinzhou Medical University, Jinzhou, Liaoning Province, P.R. China
| | - Kai Cui
- Department of Health Statistics, School of Public Health, Jinzhou Medical University, Jinzhou, Liaoning Province, P.R. China
- *Correspondence: Kai Cui, Department of Health Statistics, School of Public Health, Jinzhou Medical University, 40 Songpo Road, Jinzhou 121000, P.R. China (e-mail: )
| |
Collapse
|
2
|
Ong'ondi M, Kagotho E. Plasma Cell Leukemia: A Review of 3 Cases Managed in Kenya. Case Rep Hematol 2021; 2021:4843818. [PMID: 34395001 PMCID: PMC8363435 DOI: 10.1155/2021/4843818] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2021] [Accepted: 07/17/2021] [Indexed: 12/03/2022] Open
Abstract
Plasma Cell Leukemia (PCL) is a rare and aggressive form of plasma cell dyscrasia that can arise either de novo (primary plasma cell leukemia) or evolve from previously diagnosed and treated multiple myeloma (secondary PCL). We highlight three clinical cases with very different presentations as a reminder of this diagnosis. The cases also highlight the diversity and variability that cover a patient's journey that is highly dependent on accessibility based on financial capability and social support. The clinical presentation is more aggressive due to the higher tumour burden and more proliferative tumor cells with cytopenias being profound and more organomegaly. The diagnosis is made based on at least 20% of total white blood cells being circulating plasma cells with a peripheral blood absolute plasma cell count of at least 2 × 109/l. Treatment with novel agents followed by autologous stem cell transplant in those who are transplant eligible leads to better outcomes.
Collapse
Affiliation(s)
- Matilda Ong'ondi
- Department of Internal Medicine; Hemato-oncology Unit, Kenyatta National Hospital, Nairobi, Kenya
| | - Elizabeth Kagotho
- Department of Pathology and Laboratory Medicine, Aga Khan University hospital, Nairobi, Kenya
| |
Collapse
|